Do CYP1B1 rs1056836 GG and COMT rs4680 AA together shift estrogen metabolism toward reactive 4-hydroxyestradiol?

Clinical and mechanistic evidence

• Genetic modification of COMT activity: The catechol-O-methyltransferase (COMT) gene contains a functional single nucleotide polymorphism at rs4680 (Val158Met). The homozygous AA (Met/Met) genotype produces a thermolabile enzyme with compromised structural stability at physiological temperatures, leading to a 2- to 4-fold reduction in COMT enzymatic activity compared to the wild-type GG (Val/Val) genotype.
• Slower catechol estrogen methylation: COMT is the primary phase II enzyme responsible for the S-adenosyl-L-methionine (SAM)-dependent O-methylation of reactive catechol estrogens (e.g., 2- and 4-hydroxyestradiol) into stable, non-reactive methoxyestrogens. Due to the reduced enzymatic capacity ($V_{max}$) in AA homozygotes, the rate of catechol estrogen detoxification is severely diminished, driving an accumulation of reactive catechols.
• Upregulated estradiol 4-hydroxylation: The cytochrome P450 enzyme CYP1B1 mediates the phase I hydroxylation of estradiol. The CYP1B1 rs1056836 GG (Val/Val, Leu432Val) variant alters the active-site geometry near the heme channel, increasing the enzyme's catalytic efficiency ($V_{max}/K_m$) for the 4-hydroxylation pathway. This shifts the metabolic profile toward elevated production of 4-hydroxyestradiol (4-OHE2).
• Synergistic shift in metabolite patterns: When the high-activity CYP1B1 variant (rs1056836 GG) is paired with the low-activity COMT variant (rs4680 AA), kinetic modeling demonstrates a synergistic metabolic shift. This combination maximizes the generation of 4-OHE2 while simultaneously restricting its methylation-mediated clearance. 4-OHE2 is readily oxidized to reactive quinones that form depurinating estrogen-DNA adducts, presenting a mechanism for genomic instability.

Clinical implications

• Translational evidence: While biochemical and kinetic models robustly support this dual-variant shift toward reactive estrogen intermediates, clinical observations in human cohorts remain context-dependent. Some subgroup analyses correlate these joint genotypes with biomarkers of cumulative estrogen exposure (such as mammographic density), though direct associations with urinary estrogen-DNA adducts are often limited by sample size and systemic hormonal variations.

Bottom line

The combination of CYP1B1 rs1056836 GG and COMT rs4680 AA synergistically alters estrogen metabolism by accelerating the production of genotoxic 4-hydroxyestradiol while severely compromising its methylation-based detoxification, resulting in a systemic shift toward reactive, pro-oxidant estrogen intermediates.